Pharma / Biotech

Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder.

Related Articles

Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder.

Assay Drug Dev Technol. 2019 Oct;17(7):322-329

Authors: Mdanda S, Ntshangase S, Singh SD, Naicker T, Kruger HG, Baijnath S, Govender T

Abstract
The central nervous system has been identified as an anatomical reservoir for HIV due the difficulties in delivering therapeutic agents into the brain and this complication results in HIV-associated neurocognitive disorder that persists in infected patients. The brain regions that are potentially exposed to tissue deficits due to HIV have been reported in previous reports; therefore, it is important to determine the drugs that can enter and localize in brain regions that are known to be susceptible to HIV neurodegeneration. Sprague-Dawley rats received intraperitoneal doses of zidovudine and lamivudine (50 mg kg-1). Mass spectrometry methods were used to determine the pharmacokinetics, of zidovudine and lamivudine, in the brain using liquid chromatography tandem mass spectrometry and mass spectrometry imaging (MSI), respectively. Zidovudine and lamivudine displayed complementary pharmacokinetic curves indicating a rapid absorption and blood-brain barrier penetration of both drugs reaching Cmax at 0.5 h after single dose. MSI of coronal brain sections showed that zidovudine and lamivudine are mostly distributed in corpus callosum, globus pallidus, striatum, and the neocortex region. Mass spectrometry techniques were used to demonstrate that zidovudine and lamivudine drugs are able to reach and localize in brain regions that are targets of HIV neurodegeneration in the brain.

PMID: 31634020 [PubMed – in process]

Source link




Related posts

A novel strategy to evaluate the quality of herbal products based on the chemical profiling, efficacy evaluation and pharmacokinetics.

Newsemia

Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous hemodiafiltration: A patient case and literature review.

Newsemia

CITROMA (Magnesium Citrate) Liquid [Major Pharmaceuticals]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy